Authors:
Hellberg, MR
Sallee, VL
McLaughlin, MA
Sharif, NA
Desantis, L
Dean, TR
Zinke, PW
Citation: Mr. Hellberg et al., Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, J OCUL PH T, 17(5), 2001, pp. 421-432
Authors:
Sharif, NA
Xu, SX
Crider, JY
McLaughlin, M
Davis, TL
Citation: Na. Sharif et al., Levobetaxolol (Betaxon(TM)) and other beta-adrenergic antagonists: Preclinical pharmacology, IOP-lowering activity and sites of action in human eyes, J OCUL PH T, 17(4), 2001, pp. 305-317
Citation: Jy. Crider et Na. Sharif, Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells, J OCUL PH T, 17(1), 2001, pp. 35-46
Citation: Jy. Crider et al., Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization, PROS LEUK E, 62(1), 2000, pp. 21-26
Authors:
Ohia, SE
Opere, CA
Awe, SO
Adams, L
Sharif, NA
Citation: Se. Ohia et al., Human, bovine, and rabbit retinal glutamate-induced [H-3]D-aspartate release: Role in excitotoxicity, NEUROCHEM R, 25(6), 2000, pp. 853-860
Authors:
Sharif, NA
Crider, JY
Xu, SX
Williams, GW
Citation: Na. Sharif et al., Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: Focus on DP class prostanoids, J PHARM EXP, 293(2), 2000, pp. 321-328
Citation: Na. Sharif et al., Pharmacology and autoradiography of human DP prostanoid receptors using [H-3]-BWA868C, a DP receptor-selective antagonist radioligand, BR J PHARM, 131(6), 2000, pp. 1025-1038
Citation: Tl. Davis et Na. Sharif, Pharmacological characterization of [H-3]-prostaglandin E-2 binding to thecloned human EP4 prostanoid receptor, BR J PHARM, 130(8), 2000, pp. 1919-1926
Authors:
Yanni, JM
Sharif, NA
Gamache, DA
Miller, ST
Weimer, LK
Spellman, JM
Citation: Jm. Yanni et al., A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: Effects of new topical ocular drugs, ACT OPHTH S, 77, 1999, pp. 33-37
Citation: Tl. Davis et Na. Sharif, Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology, J OCUL PH T, 15(4), 1999, pp. 323-336
Citation: Na. Sharif et Sx. Xu, Pharmacological characterization of [H-3]-ifenprodil binding to polyamine binding sites on rabbit and rat retinal homogenates: Role in neuroprotection?, J OCUL PH T, 15(3), 1999, pp. 271-281
Authors:
Offord, EA
Sharif, NA
Mace, K
Tromvoukis, Y
Spillare, EA
Avanti, O
Howe, WE
Pfeifer, AMA
Citation: Ea. Offord et al., Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies, INV OPHTH V, 40(6), 1999, pp. 1091-1101
Citation: Na. Sharif et al., [H-3]AL-5848 ([H-3]9 beta-(+)-fluprostenol). Carboxylic acid of travoprost(AL-6221), a novel FP prostaglandin o study the pharmacology and autoradiographic localization of the FP receptor, J PHARM PHA, 51(6), 1999, pp. 685-694
Authors:
Griffin, BW
Klimko, P
Crider, JY
Sharif, NA
Citation: Bw. Griffin et al., AL-8810: A novel prostaglandin F-2 alpha analog with selective antagonist effects at the prostaglandin F-2 alpha (FP) receptor, J PHARM EXP, 290(3), 1999, pp. 1278-1284
Authors:
Yanni, JM
Weimer, LK
Sharif, NA
Xu, SX
Gamache, DA
Spellman, JM
Citation: Jm. Yanni et al., Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs, ARCH OPHTH, 117(5), 1999, pp. 643-647
Authors:
Sharif, NA
Wiernas, TK
Howe, WE
Griffin, BW
Offord, EA
Pfeifer, AMA
Citation: Na. Sharif et al., Human corneal epithelial cell functional responses to inflammatory agents and their antagonists, INV OPHTH V, 39(13), 1998, pp. 2562-2571